Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766381 | 0.89 | TYK2 (0.49) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL25316583 | 0.89 | TYK2 (0.49) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL25897700 | 0.86 | TYK2 (0.53) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL25897696 | 0.84 | TYK2 (0.38) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL29766415 | 0.84 | TYK2 (0.56) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL27238458 | 0.83 | TYK2 (0.50) | TYK2JAK1JAK2 | |
| SCHEMBL29766337 | 0.82 | TYK2 (0.43) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL25897738 | 0.82 | TYK2 (0.43) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL29766371 | 0.81 | TYK2 (0.48) | TYK2JAK1JAK2STAT3 | |
| SCHEMBL30703074 | 0.81 | TYK2 (0.34) | TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2025-01-09 | — | — | US | claimed |
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2024-10-22 | — | — | US | claimed |
| EP-4294807-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2023-12-27 | — | — | EP | claimed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | claimed |
| WO-2022175752-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-08-25 | — | — | WO | claimed |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2025-01-09 | — | — | US | disclosed |
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2024-10-22 | — | — | US | disclosed |
| CN-117377669-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4294807-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2023-12-27 | — | — | EP | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-11613548-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220281885-A1 | TYK2 INHIBITORS AND USES THEREOF | JUBILANT BIOSYS LIMITED (IN) | 2022-09-08 | — | — | US | disclosed |
| WO-2022175752-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | TYK2, JAK1, PDXK | TYK2 1/4885JAK1 2/4885JAK2 4/4885 |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 4/4885 |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 4/4885 |
| US-20220281885-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
| US-11613548-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | TYK2, TPX2, PDXK | TYK2 1/4885JAK1 6/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.